Sign In
Buy CGEN
$2.34
-0.0700 (-2.90%)
At Close: Aug 10, 2026
Why Compugen Stock Got Slammed Today
05:29pm, Monday, 15'th Nov 2021
A price cut from an analyst had some traders hitting the sell button.
Compugen Posts Q3 Loss; Shares Drop 18%
05:04pm, Monday, 15'th Nov 2021 Smarter Analyst
Shares of Compugen (CGEN) plummeted 18% to close at $5.87 on November 12 after the Israel-based cancer immunotherapy company reported a loss for The post Compugen Posts Q3 Loss; Shares Drop 18% appeared first on Smarter Analyst .
Compugen Ltd. (NASDAQ: CGEN): Performance Report And Growth Forecast
01:30pm, Monday, 15'th Nov 2021 Marketing Sentinel
In the last trading session, 6.19 million Compugen Ltd. (NASDAQ:CGEN) shares changed hands as the companys beta touched 2.28. With the companys per share price at $5.87 changed hands at -$1.29 or -18.02% during last session, the market valuation stood at $600.91M. CGENs last price was a discount, traded about -158.26% off its 52-week high Compugen Ltd. (NASDAQ: CGEN): Performance Report And Growth Forecast Read More »
Compugen Ltd. (CGEN) CEO Anat Cohen-Dayag on Q3 2021 Results - Earnings Call Transcript
01:51pm, Friday, 12'th Nov 2021
Compugen Ltd. (CGEN) CEO Anat Cohen-Dayag on Q3 2021 Results - Earnings Call Transcript
Compugen (CGEN) Stock Up on Bristol Myers' $20M Investment
11:33am, Friday, 12'th Nov 2021
Compugen (CGEN) announces an expansion of its collaboration agreement with Bristol Myers Squibb and a $20 million equity investment by the latter.
Why Compugen Surged 14% Higher on Thursday
06:05pm, Thursday, 11'th Nov 2021
The company is deepening its partnership with Bristol Myers Squibb.
Compugen (CGEN) Stock: Why The Price Jumped
07:43am, Thursday, 11'th Nov 2021
The stock price of Compugen Ltd. (NASDAQ: CGEN) increased by over 15% pre-market today.
Compugen To Present Clinical Data from anti-TIGIT COM902 Monotherapy and Triple Combination Dose Escalation Studies at SITC 2021
08:05am, Friday, 01'st Oct 2021
HOLON, Israel, Oct. 1, 2021 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced that new clinica
Compugen to Present at the Cantor Global Healthcare Conference
09:00am, Tuesday, 14'th Sep 2021
HOLON, Israel, Sept. 14, 2021 /PRNewswire/ -- Compugen Ltd.
Compugen to Present at the Morgan Stanley 19th Annual Global Healthcare Conference
07:00am, Thursday, 26'th Aug 2021
HOLON, Israel, Aug. 26, 2021 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a leader in predictive discovery and development of first-in-class therapeutics for cancer immunotherapy, today announced t
This Unknown Biotech Has a Secret Weapon for Outsized Returns
07:19am, Saturday, 21'st Aug 2021
Bio-Rad's equity position in a German pharma company is an asset many investors may not realize.
Why Compugen Stock Is Rising Again Today
11:41am, Thursday, 29'th Jul 2021
Momentum is carrying over from the company's second-quarter update on Wednesday.
Compugen Ltd (CGEN) CEO Anat Cohen-Dayag on Q2 2021 Results - Earnings Call Transcript
03:10pm, Wednesday, 28'th Jul 2021
Compugen Ltd (CGEN) CEO Anat Cohen-Dayag on Q2 2021 Results - Earnings Call Transcript
Why Compugen Stock Is Jumping Today
12:12pm, Wednesday, 28'th Jul 2021
Investors were especially interested in the company's pipeline update.
HOLON, Israel, July 19, 2021 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced that the first
